Factor Xa inhibitor used with liver-derived progenitor cells

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9775890
SERIAL NO

14374730

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to compositions and methods for cell transplantation. In particular, the present invention provides a composition comprising procoagulant cells and at least one factor Xa inhibitor, preferably rivaroxaban, as well as at least one thrombin inhibitor, preferably bivalirudin.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
UNIVERSITE CATHOLIQUE DE LOUVAIN1348 LOUVAIN-LA-NEUVE

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Eeckhoudt, Stéphane Erbisoeul, BE 3 19
Hermans, Cédric Brussels, BE 3 19
Najimi, Mustapha Brussels, BE 13 51
Sokal, Etienne Hoeilaart, BE 21 87
Stephenne, Xavier Rixensart, BE 4 26

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Apr 3, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Apr 3, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00